Premium
LOVASTATIN POTENTIATES THE PHOTOCYTOTOXIC EFFECT OF PHOTOFRIN II DELIVERED TO HT29 HUMAN COLONIC ADENOCARCINOMA CELLS BY LOW DENSITY LIPOPROTEIN
Author(s) -
Biade S.,
Mazière J. C.,
Mora L.,
Santus R.,
Mazière C.,
Auclair M.,
Morlière P.,
Dubertret L.
Publication year - 1993
Publication title -
photochemistry and photobiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.818
H-Index - 131
eISSN - 1751-1097
pISSN - 0031-8655
DOI - 10.1111/j.1751-1097.1993.tb02303.x
Subject(s) - lovastatin , photodynamic therapy , chemistry , reductase , low density lipoprotein , cancer research , lipoprotein , coenzyme a , pharmacology , biochemistry , hmg coa reductase , photosensitizer , enzyme , cholesterol , biology , photochemistry , organic chemistry
A 24 h preculture of HT29–18human colonic adenocarcinoma cells with the sterol synthesis inhibitor lovastatin at concentrations of 0.1‐0.5 μM markedly increased the photocytotoxic effect of photofrin II delivered to cells by low density lipoproteins. Under the same conditions, LDL binding and photofrin II (PII) uptake by HT29 cells increased about 1.8‐fold and 1.5‐fold, respectively. These results suggest that hydroxymethylglutaryl‐coenzyme A reductase inhibitors could be useful for potentiating the photodynamic therapy of tumors by PII.